Pharmaceutical companies to benefit from new blood cancer drugs
Blood cancer drugs represent a growth opportunity for the pharmaceutical industry over the next few years, Moody's Investors Service says in a new report, titled Blood Cancer Breakthroughs Will Benefit J&J, Roche and Others. The US Food and Drug Administration has granted breakthrough therapy designation to several new pipeline drugs to treat these cancers, and two have already been approved.
"New revenue opportunities from blood cancer drugs are large, and many are incremental," says Moody’s senior vice president, Michael Levesque, adding: "We believe the biggest opportunities are in treatments for chronic lymphocytic leukemia, non-Hodgkin's lymphoma and multiple myeloma."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze